Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | TCT 2021: what to look forward to

Akshay Sharma • 2 Feb 2021
TCT 2021
Leukemia

Akshay Sharma, MBBS, St. Jude Children’s Research Hospital, Memphis, TN, discusses the upcoming Transplantation & Cellular Therapy (TCT) 2021 virtual meeting, including exciting updates in the treatment of graft-versus-host disease, as well as the use of cellular therapies in hematological malignancies. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Akshay Sharma

1:45
Impact of cytogenetic abnormalities on OS following SCT in pediatric AML
Akshay Sharma • 12 Dec 2022
1:44
Phase II study of MGTA-145 in combination with plerixafor for HSC mobilization in patients with SCD
Akshay Sharma • 12 Dec 2022
0:56
Treatment of severe SCD with OTQ923 CRISPR/Cas9 gene therapy
Akshay Sharma • 12 Dec 2022
2:43
A machine learning model to improve outcome prediction following allogeneic transplantation
Akshay Sharma • 12 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals